Neumora Therapeutics (NMRA) Change in Account Payables (2022 - 2026)

Neumora Therapeutics' Change in Account Payables history runs 5 years deep, the most recent figure standing at $1.7 million for Q1 2026.

• In Q1 2026, Change in Account Payables rose 174.41% year-over-year to $1.7 million; the TTM figure through Mar 2026 stood at $4.0 million (up 845.62% YoY), while the FY2025 annual figure was $71000.0, down 97.53% from the prior year.
• Change in Account Payables for Q1 2026 stood at $1.7 million, down from $2.8 million in the prior quarter.
• The five-year high for Change in Account Payables was $7.0 million in Q2 2023, with the low at -$6.0 million in Q1 2023.
• The 5-year median for Change in Account Payables is -$252000.0 (2025), against an average of $66571.4.
• The sharpest annual moves came in 2024 and 2025: Change in Account Payables surged 1542.16% in 2024, then tumbled 295.24% in 2025.
• Neumora Therapeutics' Change in Account Payables stood at -$3.1 million in 2022, then surged by 38.5% to -$1.9 million in 2023, then slumped by 51.52% to -$2.9 million in 2024, then surged by 197.69% to $2.8 million in 2025, then plunged by 40.71% to $1.7 million in 2026.
• Business Quant data shows NMRA's Change in Account Payables at $1.7 million in Q1 2026, $2.8 million in Q4 2025, and -$96000.0 in Q3 2025.